

Supplementary Table 2. Prescription rates of SGLT2 inhibitors and RAS blockers in DKD patients (2012 to 2019)

	2012	2013	2014	2015	2016	2017	2018	2019
Prescription rate of SGLT2 inhibitors								
DKD stage (eGFR, mL/min/1.73 m ²)								
DKD stage 1 (≥90)	-	-	0.24	2.45	0.41	9.06	11.89	14.71
DKD stage 2 (60–89)	-	-	0.15	1.51	3.33	5.64	7.35	9.24
DKD stage 3 (30–59)	-	-	0.12	1.08	2.29	3.89	4.95	6.34
DKD stage 4 (15–29)	-	-	0.09	0.59	1.17	2.13	2.6	3.17
ESKD (<15)	-	-	0.03	0.21	0.58	0.76	1.28	1.99
DKD (<60)	-	-	0.11	1.02	2.16	3.65	4.65	5.94
Prescription rate of RAS blockers								
DKD stage (eGFR, mL/min/1.73 m ²)								
DKD stage 1 (≥90)	43.18	43.82	44.27	43.62	3.26	43.22	43.42	43.93
DKD stage 2 (60–89)	51.89	52.83	53.34	52.97	52.55	52.13	52.06	52.33
DKD stage 3 (30–59)	71.08	71.58	72.1	71.78	70.73	70.07	69.31	69.88
DKD stage 4 (15–29)	85.67	8.77	83.86	85	83.67	81.67	81.48	80.71
ESKD (<15)	70.51	69.67	67.79	66.41	65.92	64.18	63.26	62.1
DKD (<60)	71.96	67.09	72.76	72.49	71.43	70.66	69.92	70.34

SGLT2, sodium glucose cotransporter 2; RAS, renin-angiotensin system; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease.